Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Candriam S.C.A. Purchases 51,296 Shares of Biogen Inc. $BIIB

📈 Candriam S.C.A. increased its Biogen holdings by 15.5% in Q1, acquiring 51,296 shares to reach a total stake of 381,768 shares valued at $69.99 million.

📊 Other institutional investors including Rothschild Investment LLC and Itau Unibanco Holding S.A. also increased their stakes in Biogen during recent quarters.

📉 HSBC maintained a 'reduce' rating with a $157 price target, contrasting with Freedom Capital's upgrade to 'strong-buy' and JPMorgan Chase raising its target to $185.

💰 Biogen reported Q4 EPS of $3.57, beating analyst estimates of $2.95, while revenue reached $2.48 billion against expectations of $2.29 billion.

📈 Revenue grew 1.9% year-over-year to $2.48 billion, with the company achieving a net margin of 13.81% and return on equity of 12.83%.

🎯 The company provided FY 2026 guidance for EPS between $14.25 and $15.25, slightly above analyst forecasts of $13.77.

📉 Biogen's stock price opened at $199.15, trading above its 50-day moving average of $198.25 but below its 200-day moving average of $188.07.

🏢 The firm holds a market capitalization of $29.40 billion with a price-to-earnings ratio of 21.37 and a low debt-to-equity ratio of 0.34.

💊 Biogen focuses on therapies for neurological diseases including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

📉 The consensus analyst rating is 'Moderate Buy' with a collective price target of $218.15.

Bullish Signals
  • Candriam S.C.A., a major institutional investor, significantly increased its position by 15.5% in Q1, signaling confidence in the company's long-term prospects.
  • Biogen reported quarterly EPS of $3.57, which beat analyst consensus estimates of $2.95 by $0.62, demonstrating strong profitability.
  • Revenue of $2.48 billion exceeded analyst expectations of $2.29 billion, indicating robust commercial performance in the biotechnology sector.
  • The company achieved a net margin of 13.81% and a return on equity of 12.83%, reflecting efficient operations and strong financial health.
  • Analyst Freedom Capital upgraded Biogen to a 'strong-buy' rating, contributing to a consensus 'Moderate Buy' sentiment among sell-side analysts.
  • Biogen's full-year 2026 guidance of $14.25-$15.25 EPS exceeds the current analyst forecast of $13.77, suggesting positive future growth expectations.
  • The stock trades with a low debt-to-equity ratio of 0.34 and a quick ratio of 2.41, indicating a strong balance sheet and liquidity position.
Risk Factors
  • HSBC reiterated a 'reduce' rating with a price target of $157, which is significantly below the current trading price and consensus target.
  • Truist Financial reduced its price target from $193.00 to $189.00 and maintained a 'hold' rating, reflecting some caution among analysts.
  • The stock's 200-day moving average of $188.07 is below the current trading price, but the 50-day moving average of $198.25 suggests recent volatility or consolidation.
Full Analysis
Candriam S.C.A. increased its stake in Biogen Inc. (NASDAQ:BIIB) by 15.5% during the first quarter, purchasing an additional 51,296 shares to hold a total of 381,768 shares valued at approximately $69.99 million. This move represents a significant institutional accumulation, with Candriam now owning roughly 0.26% of the company's outstanding stock. Several other hedge funds and institutional investors also adjusted their positions in BIIB during recent quarters, though their individual stakes remain relatively small compared to major holders. Analyst sentiment regarding Biogen remains mixed but leans positive based on consensus metrics. HSBC reiterated a 'reduce' rating with a $157 price target, while Freedom Capital upgraded the stock to a 'strong-buy'. Other analysts like Truist Financial and JPMorgan Chase adjusted their price targets downward or upward respectively, resulting in a consensus rating of 'Moderate Buy' and a consensus price target of $218.15. Biogen recently reported strong quarterly financial results that exceeded analyst expectations. The company posted earnings per share (EPS) of $3.57 against a consensus estimate of $2.95, driven by revenue of $2.48 billion which surpassed the expected $2.29 billion. Revenue grew 1.9% year-over-year, and the firm maintained healthy margins with a net margin of 13.81%. The company has provided full-year 2026 guidance ranging between $14.25 and $15.25 EPS.